Intraoperative Radiation Therapy
Colorado’s First Zeiss Intrabeam Technology
For early stage breast cancer patients, Intraoperative Radiation Therapy (IORT) can be both a timesaver and a lifesaver. The Zeiss INTRABEAM IORT system at Littleton Adventist Hospital delivers a 20-30 minute, targeted dose of radiation directly to the tumor site during surgery. This direct radiation treatment helps to destroy any microscopic tumor cells that may be left behind and reduces the risk of recurrence. This technology offers breast cancer patients with small, early-stage tumors the opportunity to have their treatments done in one day with minimal recovery time or symptoms and move on with their lives.
Benefits may include:
Treatment time reduced from an average of six weeks to a single dose during surgery
IORT can be done as a second procedure as well. The patient can have their lumpectomy at another hospital and then come to Littleton Adventist Hospital for the radiation portion. It is a second, but brief, surgical procedure for the patient.
We chose the Zeiss INTRABEAM system for our patients because it is supported by positive outcomes obtained during more than 12 years of clinical use, including evaluation as the sole IORT system used in the TARGIT-A clinical trial, the largest randomized clinical trial conducted in the field of IORT.
As an NAPBC comprehensive breast cancer center, we are proud to add IORT to the list of services we provide here at Littleton Adventist Hospital and believe it speaks to our mission of improving care and quality of life for our breast cancer patients. Our IORT team of experts is led by Darlene Bugoci, MD, our radiation oncology medical director, and Jodi Widner, MD, co-medical director of our breast program, and includes breast surgeons, radiation oncologists, medical oncologists, medical physicists and surgical staff.
For more information contact Ellen Buchannan, Breast Cancer Nurse Navigator, at 303-738-7787
For more information you can also view our Breast Care Video section, TARGIT-A Trial at 2012 ASCO Breast Cancer Symposium Jayant S. Vaidya, MD, PhD, and TARGIT for breast cancer - Part 1 and 2.